Global Lipids Market - Industry Trends and Forecast to 2030

Description

List of Tables

The global lipids market is projected to register a substantial CAGR of 8.4% from 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Global Lipids Market, By Type (Natural Lipids and Synthetic Lipids), Lipid System (Neutral Lipids, Bacterial Lipids, Fluorescent Lipids, Bioactive Lipids, Polymerizable Lipids, Headgroup Modified Lipids, and Others), Delivery System (Liposomes, Solid Lipid Nanoparticles, Nanostructures Lipid Carrier, Niosomes, Transferosomes, and others), Source (Eggyolk, Soyabean, Non-GMO Soyabean, Purified Oils, Purified Fatty Acids, and Others), End User (Pharmaceutical Industries, Biotechnology Industries, Academic and Research Institutes, Cosmetic Industries, and Others), Distribution Channel (Direct Tender, Retail Sales and, Others), Country (U.S., Canada, Mexico, Germany, France, U.K, Italy, Spain, Netherland, Russia, Switzerland, Turkey, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, and Rest of Middle East and Africa) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of global lipids market are:

Growing healthcare expenditure

Improved diagnostic processes and techniques

Improved imaging techniques

Market Players:

The key market players in the global lipids market are listed below:

Alnylam Pharmaceutical, Inc.

Croda International Plc.

Moderna Inc.

BioNTech SE.

Pfizer Inc.

Evonik Industries AG

Lipoid GmbH

Matreya LLC

VAV Life Sciences Pvt Ltd.

Curia Global Inc.

Cargill, Incorporated

Gattefosse

CD Bioparticles

Merck KGaA

NOF EUROPE GmbH

ABITEC

Cayman Chemical

CordenPharma International

CHEMI S.p.A.

DSM

BASF SE

Tokyo Chemical Industry Co., Ltd.

ADMSIO

Stepan Company

Kerry

1 INTRODUCTION 45

1.1 OBJECTIVES OF THE STUDY 45
1.2 MARKET DEFINITION 45
1.3 OVERVIEW OF GLOBAL LIPIDS MARKET 45
1.4 LIMITATIONS 47
1.5 MARKETS COVERED 47

2 MARKET SEGMENTATION 51

2.1 MARKETS COVERED 51
2.2 GEOGRAPHICAL SCOPE 52
2.3 YEARS CONSIDERED FOR THE STUDY 53
2.4 CURRENCY AND PRICING 53
2.5 DBMR TRIPOD DATA VALIDATION MODEL 54
2.6 MULTIVARIATE MODELLING 57
2.7 TYPE LIFELINE CURVE 57
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 58
2.9 DBMR MARKET POSITION GRID 59
2.10 MARKET END USER COVERAGE GRID 60
2.11 VENDOR SHARE ANALYSIS 61
2.12 SECONDARY SOURCES 62
2.13 ASSUMPTIONS 62

3 EXECUTIVE SUMMARY 63

4 PREMIUM INSIGHTS 66

4.1 PESTEL ANALYSIS 69
4.2 PORTER'S FIVE FORCES 70
4.3 MERGER AND ACQUISITION, GLOBAL LIPIDS MARKET 71
4.4 PATENT ANALYSIS, GLOBAL LIPIDS MARKET 72
4.5 DRUG TREATMENT RATE BY MATURED MARKETS 73
4.6 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATE 74
4.7 KEY PRICING STRATEGIES 75
4.8 KEY PATIENT ENROLLMENT STRATEGIES 76
4.9 PRICE ANALYSIS, GLOBAL LIPIDS MARKET 77
4.10 GLOBAL LIPIDS MARKET, CLINICAL TRIALS 79
4.11 GLOBAL LIPIDS MARKET, DISTRIBUTION OF PRODUCTS BY PHASE 80
4.12 GLOBAL LIPIDS MARKET, PIPELINE ANALYSIS 81
4.13 PHASE I CANDIDATES 81
4.14 PHASE I/II CANDIDATES 82
4.15 PHASE II CANDIDATES 83
4.16 PHASE III CANDIDATES 84

5 GLOBAL LIPIDS MARKET, REGULATORY FRAMEWORK 85

5.1 REGULATION IN THE U.S.: 85
5.2 REGULATION IN EUROPE: 86

6 MARKET OVERVIEW 87

6.1 DRIVERS 89
- 6.1.1 INCREASE IN THE PREVALENCE OF CHRONIC DISEASES 89
- 6.1.2 RISE IN DEMAND FOR LIPIDS IN FOOD AND BEVERAGE AS WELL AS THE COSMETIC INDUSTRY 89
- 6.1.3 INCREASE IN DRUG DEVELOPMENT 90
6.2 RESTRAINTS 90
- 6.2.1 HIGH COST OF LIPID SYNTHESIS AND INCREASING COST OF RAW MATERIALS 90
- 6.2.2 STRICT GOVERNMENT REGULATIONS 91
6.3 OPPORTUNITIES 92
- 6.3.1 RISE IN HEALTHCARE EXPENDITURE 92
- 6.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS 92
6.4 CHALLENGES 93
- 6.4.1 DIFFERENT MANUFACTURING CHALLENGES FOR LIPID NANOPARTICLE PRODUCTION 93
- 6.4.2 LACK OF HEALTHCARE FACILITIES IN EMERGING ECONOMIES 93

7 GLOBAL LIPIDS MARKET, BY TYPE 94

7.1 OVERVIEW 95
7.2 NATURAL LIPID 98
- 7.2.1 UNSATURATED PHOSPHOLIPID 98
- 7.2.2 HYDROGENATED PHOSPHOLIPID 99
- 7.2.3 SPHINGOMYELIN 99
- 7.2.4 GLYCEROLPHOSPHOCHOLINE 99
7.3 SYNTHETIC LIPID 99
- 7.3.1 PEGYLATED PHOSPHOLIPIDS 100
- 7.3.2 PHOSPHATIDYLSERINE 100
- 7.3.3 PHOSPHATIDYGLYCEROLS 100
- 7.3.4 PHOSPHATIDYLETHANOLAMINE 100
- 7.3.5 PHOSPHATIDYLCHOLINE 100
- 7.3.6 PHOSPHATIDIC ACIDS 100

8 GLOBAL LIPIDS MARKET, BY LIPID SYSTEMS 101

8.1 OVERVIEW 102
8.2 BIOACTIVE LIPIDS 105
- 8.2.1 PLANT LIPIDS 106
- 8.2.2 LIPID ACTIVATORS 106
- 8.2.3 LIPID INHIBITORS 106
- 8.2.4 AGONISTS 106
- 8.2.5 BIOACTIVE CERAMIDES 106
- 8.2.6 ACYL CARNITINE LIPIDS 106
- 8.2.7 ENDOCANNABINOIDS 107
- 8.2.8 LIPO-NUCLEOTIDES 107
- 8.2.9 LYSYL-PHOSPHATIDYLGLYCEROL 107
- 8.2.10 DIACYLGLYCEROL PYROPHOSPHATE (DGPP) 107
8.3 POLYMERIZABLE LIPIDS 107
- 8.3.1 FUNCTIONAL PEG LIPIDS 108
- 8.3.2 MPEG STEROLS 108
- 8.3.3 MPEG CERAMIDES 108
- 8.3.4 MPEG PHOSPHOLIPIDS 108
- 8.3.5 MPEG GLYCERIDES 108
8.4 FLUORESCENT LIPIDS 109
- 8.4.1 FLUORESCENT SPHINGOLIPIDS 110
- 8.4.2 FLUORESCENT GLYCEROLIPIDS 110
- 8.4.3 FLUORESCENT PEG LIPIDS 110
- 8.4.4 FLUORESCENT PHOSPHOLIPIDS 110
- 8.4.5 FLUORESCENT STEROLS 110
- 8.4.6 OTHERS 110
8.5 BACTERIAL LIPIDS 111
- 8.5.1 MYCOLIC LIPIDS 112
- 8.5.2 N-ACYLHOMOSERINE LIPIDS 112
- 8.5.3 BRANCHED LIPIDS 112
- 8.5.4 CYCLOPROPYL LIPIDS 112
8.6 NEUTRAL LIPIDS 112
- 8.6.1 PRENOLS 113
- 8.6.2 VERY LONG CHAIN FATTY ACIDS 113
- 8.6.3 GLYCERIDES 113
- 8.6.4 EICSANOIDS 113
- 8.6.5 OXYGENATED FATTY ACIDS 113
- 8.6.6 GLYCOSYLATED DIACYL GLYCEROLS 113
- 8.6.7 PROSTAGLANDINS 113
8.7 HEADGROUP MODIFIED LIPIDS 114
- 8.7.1 FUNCTIONAL LIPIDS 115
- 8.7.2 ANTIGENIC LIPIDS 115
- 8.7.3 GLYCOSYLATED LIPIDS 115
- 8.7.4 CHELATORS 115
- 8.7.5 ADHESIVE LIPIDS 115
- 8.7.6 SNAP-TAG REACTING LIPIDS 115
- 8.7.7 ALKYL PHOSPHATES 115
8.8 OTHERS 116

9 GLOBAL LIPIDS MARKET, BY DELIVERY SYSTEMS 117

9.1 OVERVIEW 118
9.2 LIPOSOMES 121
- 9.2.1 LIPOSOMES FOR DNA/RNA 122
  - 9.2.1.1 DOTAP LIPOSOMES FOR DNA/RNA DELIVERY 122
  - 9.2.1.2 DDAB LIPOSOMES FOR DNA/RNA DELIVERY 122
  - 9.2.1.3 GL-67 LIPOSOMES FOR DNA/RNA DELIVERY 122
  - 9.2.1.4 DC-CHOLESTEROL LIPOSOMES FOR DNA/RNA DELIVERY 122
  - 9.2.1.5 DOTMA LIPOSOMES FOR DNA/RNA DELIVERY 123
  - 9.2.1.6 DODAP LIPOSOMES FOR DNA/RNA DELIVERY 123
- 9.2.2 REACTIVE LIPOSOMES 123
  - 9.2.2.1 SUCCINYL LIPOSOMES 123
  - 9.2.2.2 DBCO LIPOSOMES 123
  - 9.2.2.3 BIOTINYLATED LIPOSOMES 124
  - 9.2.2.4 CARBOXYLIC ACID LIPOSOMES 124
  - 9.2.2.5 AMINE LIPOSOMES 124
  - 9.2.2.6 CYANUR LIPOSOMES 124
  - 9.2.2.7 AZIDE LIPOSOMES 124
  - 9.2.2.8 FOLATE LIPOSOMES 124
  - 9.2.2.9 DODECANYL LIPOSOMES 124
  - 9.2.2.10 NI REACTIVE LIPOSOMES 124
  - 9.2.2.11 PDP LIPOSOMES 124
  - 9.2.2.12 GLUTARYL LIPOSOMES 124
  - 9.2.2.13 OTHERS 124
- 9.2.3 DRUG LOADED LIPOSOMES 125
- 9.2.4 PLAIN LIPOSOMES 125
  - 9.2.4.1 CARDIOLIPIN LIPIDS LIPOSOMES 125
  - 9.2.4.2 DOTAP LIPOSOMES 125
  - 9.2.4.3 PHOSPHATIDYLSERINE LIPOSOMES 125
  - 9.2.4.4 PHOSPHATIDYLCHOLINE LIPOSOMES 125
  - 9.2.4.5 PHOSPHATIDYL GLYCEROL LIPOSOMES 125
  - 9.2.4.6 OTHERS 126
9.3 SOLID LIPID NANOPARTICLES 126
9.4 NANOSTRUCTURES LIPID CARRIER 127
9.5 TRANSFEROSOMES 128
9.6 NIOSOMES 129
9.7 OTHERS 130

10 GLOBAL LIPIDS MARKET, BY SOURCE 131

10.1 OVERVIEW 132
10.2 PURIFIED FATTY ACIDS 135
10.3 PURIFIED OILS 136
10.4 EGG YOLK 137
10.5 SOYABEAN 138
10.6 NON-GMO SOYABEAN 139
10.7 OTHERS 140

11 GLOBAL LIPIDS MARKET, BY END USER 141

11.1 OVERVIEW 142
11.2 PHARMACEUTICAL INDUSTRIES 145
11.3 BIOTECHNOLOGY INDUSTRIES 146
11.4 COSMETIC INDUSTRIES 147
11.5 ACADEMIC AND RESEARCH INSTITUTES 147
11.6 OTHERS 148

12 GLOBAL LIPIDS MARKET, BY DISTRIBUTION CHANNEL 149

12.1 OVERVIEW 150
12.2 DIRECT TENDER 153
12.3 RETAIL SALES 154
12.4 OTHERS 155

13 GLOBAL LIPIDS MARKET, BY REGION 156

13.1 OVERVIEW 157
13.2 NORTH AMERICA 163
- 13.2.1 U.S. 175
- 13.2.2 CANADA 182
- 13.2.3 MEXICO 189
13.3 EUROPE 196
- 13.3.1 GERMANY 208
- 13.3.2 U.K. 215
- 13.3.3 ITALY 222
- 13.3.4 SPAIN 229
- 13.3.5 FRANCE 236
- 13.3.6 SWITZERLAND 243
- 13.3.7 BELGIUM 250
- 13.3.8 NETHERLANDS 257
- 13.3.9 RUSSIA 264
- 13.3.10 TURKEY 271
- 13.3.11 REST OF EUROPE 278
13.4 ASIA-PACIFIC 279
- 13.4.1 CHINA 291
- 13.4.2 JAPAN 298
- 13.4.3 SOUTH KOREA 305
- 13.4.4 INDIA 312
- 13.4.5 AUSTRALIA 319
- 13.4.6 SINGAPORE 326
- 13.4.7 THAILAND 333
- 13.4.8 MALAYSIA 340
- 13.4.9 INDONESIA 347
- 13.4.10 PHILIPPINES 354
- 13.4.11 REST OF ASIA PACIFIC 361
13.5 SOUTH AMERICA 362
- 13.5.1 BRAZIL 374
- 13.5.2 ARGENTINA 381
- 13.5.3 REST OF SOUTH AFRICA 388
13.6 MIDDLE EAST AND AFRICA 389
- 13.6.1 SOUTH AFRICA 401
- 13.6.2 SAUDI ARABIA 408
- 13.6.3 U.A.E. 415
- 13.6.4 EGYPT 422
- 13.6.5 ISRAEL 429
- 13.6.6 REST OF MIDDLE EAST AND AFRICA 436

14 GLOBAL LIPIDS MARKET: COMPANY LANDSCAPE 437

14.1 COMPANY SHARE ANALYSIS: GLOBAL 437
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 438
14.3 COMPANY SHARE ANALYSIS: EUROPE 439
14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 440

15 SWOT ANALYSIS 441

16 COMPANY PROFILE 442

16.1 BIONTECH SE. 442
- 16.1.1 COMPANY SNAPSHOT 442
- 16.1.2 REVENUE ANALYSIS 443
- 16.1.3 COMPANY SHARE ANALYSIS 443
- 16.1.4 PRODUCT PORTFOLIO 443
- 16.1.5 RECENT DEVELOPMENT 444
16.2 MODERNA, INC. 445
- 16.2.1 COMPANY SNAPSHOT 445
- 16.2.2 REVENUE ANALYSIS 445
- 16.2.3 COMPANY SHARE ANALYSIS 446
- 16.2.4 PRODUCT PORTFOLIO 446
- 16.2.5 RECENT DEVELOPMENTS 446
16.3 PFIZER INC. 447
- 16.3.1 COMPANY SNAPSHOT 447
- 16.3.2 REVENUE ANALYSIS 447
- 16.3.3 COMPANY SHARE ANALYSIS 448
- 16.3.4 PRODUCT PORTFOLIO 448
- 16.3.5 RECENT DEVELOPMENTS 448
16.4 CARGILL, INCORPORATED. 449
- 16.4.1 COMPANY SNAPSHOT 449
- 16.4.2 COMPANY SHARE ANALYSIS 449
- 16.4.3 PRODUCT PORTFOLIO 449
- 16.4.4 RECENT DEVELOPMENTS 449
16.5 KERRY. 450
- 16.5.1 COMPANY SNAPSHOT 450
- 16.5.2 COMPANY SHARE ANALYSIS 450
- 16.5.3 PRODUCT PORTFOLIO 451
- 16.5.4 RECENT DEVELOPMENTS 451

16.6 ABITEC 452
- 16.6.1 COMPANY SNAPSHOT 452
- 16.6.2 PRODUCT PORTFOLIO 452
- 16.6.3 RECENT DEVELOPMENTS 452
16.7 ADMSIO 454
- 16.7.1 COMPANY SNAPSHOT 454
- 16.7.2 PRODUCT PORTFOLIO 454
- 16.7.3 RECENT DEVELOPMENTS 454
16.8 ALNYLAM PHARMACEUTICALS, INC. 455
- 16.8.1 COMPANY SNAPSHOT 455
- 16.8.2 REVENUE ANALYSIS 455
- 16.8.3 PRODUCT PORTFOLIO 456
- 16.8.4 RECENT DEVELOPMENT 456
16.9 BASF SE 457
- 16.9.1 COMPANY SNAPSHOT 457
- 16.9.2 REVENUE ANALYSIS 458
- 16.9.3 PRODUCT PORTFOLIO 458
- 16.9.4 RECENT DEVELOPMENTS 458
16.10 CAYMAN CHEMICAL 459
- 16.10.1 COMPANY SNAPSHOT 459
- 16.10.2 PRODUCT PORTFOLIO 459
- 16.10.3 RECENT DEVELOPMENTS 459
16.11 CD BIOPARTCLES. 460
- 16.11.1 COMPANY SNAPSHOT 460
- 16.11.2 PRODUCT PORTFOLIO 460
- 16.11.3 RECENT DEVELOPMENTS 460
16.12 CHEMI S.P.A. 461
- 16.12.1 COMPANY SNAPSHOT 461
- 16.12.2 PRODUCT PORTFOLIO 461
- 16.12.3 RECENT DEVELOPMENTS 461
16.13 CORDENPHARMA INTERNATIONAL 462
- 16.13.1 COMPANY SNAPSHOT 462
- 16.13.2 PRODUCT PORTFOLIO 462
- 16.13.3 RECENT DEVELOPMENTS 462
16.14 CRODA INTERNATIONAL PLC. 464
- 16.14.1 COMPANY SNAPSHOT 464
- 16.14.2 PRODUCT PORTFOLIO 464
- 16.14.3 RECENT DEVELOPMENTS 464
16.15 CURIA GLOBAL, INC. 465
- 16.15.1 COMPANY SNAPSHOT 465
- 16.15.2 PRODUCT PORTFOLIO 465
- 16.15.3 RECENT DEVELOPMENT 465
16.16 DSM 467
- 16.16.1 COMPANY SNAPSHOT 467
- 16.16.2 PRODUCT PORTFOLIO 467
- 16.16.3 RECENT DEVELOPMENTS 467
16.17 EVONIK INDUSTRIES AG 468
- 16.17.1 COMPANY SNAPSHOT 468
- 16.17.2 PRODUCT PORTFOLIO 468
- 16.17.3 RECENT DEVELOPMENTS 468
16.18 GATTEFOSSE 470
- 16.18.1 COMPANY SNAPSHOT 470
- 16.18.2 PRODUCT PORTFOLIO 470
- 16.18.3 RECENT DEVELOPMENTS 470
16.19 LIPOID GMBH 471
- 16.19.1 COMPANY SNAPSHOT 471
- 16.19.2 PRODUCT PORTFOLIO 471
- 16.19.3 RECENT DEVELOPMENT 472
16.20 MATREYA, LLC 473
- 16.20.1 COMPANY SNAPSHOT 473
- 16.20.2 PRODUCT PORTFOLIO 473
- 16.20.3 RECENT DEVELOPMENTS 473
16.21 MERCK KGAA 474
- 16.21.1 COMPANY SNAPSHOT 474
- 16.21.2 PRODUCT PORTFOLIO 474
- 16.21.3 RECENT DEVELOPMENTS 474
16.22 NOF EUROPE GMBH 475
- 16.22.1 COMPANY SNAPSHOT 475
- 16.22.2 PRODUCT PORTFOLIO 475
- 16.22.3 RECENT DEVELOPMENTS 475
16.23 STEPAN COMPANY 476
- 16.23.1 COMPANY SNAPSHOT 476
- 16.23.2 PRODUCT PORTFOLIO 476
- 16.23.3 RECENT DEVELOPMENTS 476
16.24 TOKYO CHEMICAL INDUSTRY CO., LTD. 478
- 16.24.1 COMPANY SNAPSHOT 478
- 16.24.2 PRODUCT PORTFOLIO 478
- 16.24.3 RECENT DEVELOPMENTS 478
16.25 VAV LIFE SCIENCES PVT LTD 479
- 16.25.1 COMPANY SNAPSHOT 479
- 16.25.2 PRODUCT PORTFOLIO 479
- 16.25.3 RECENT DEVELOPMENTS 479

17 QUESTIONNAIRE 480

18 RELATED REPORTS 484

LIST OF FIGURES

FIGURE 1 GLOBAL LIPIDS MARKET: SEGMENTATION 51
FIGURE 2 GLOBAL LIPIDS MARKET: DATA TRIANGULATION 54
FIGURE 3 GLOBAL LIPIDS MARKET: DROC ANALYSIS 55
FIGURE 4 GLOBAL LIPIDS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 56
FIGURE 5 GLOBAL LIPIDS MARKET: COMPANY RESEARCH ANALYSIS 56
FIGURE 6 GLOBAL LIPIDS MARKET: INTERVIEW DEMOGRAPHICS 58
FIGURE 7 GLOBAL LIPIDS MARKET: DBMR MARKET POSITION GRID 59
FIGURE 8 GLOBAL LIPIDS MARKET: MARKET END USER COVERAGE GRID 60
FIGURE 9 GLOBAL LIPIDS MARKET: VENDOR SHARE ANALYSIS 61
FIGURE 10 GLOBAL LIPIDS MARKET: SEGMENTATION 65
FIGURE 11 THE GROWING PRVALENCE OF CHRONIC DISEASES AND RISING DEMAND FOR LIPIDS IN VARIOUS INDUSTRIES ARE EXPECTED TO DRIVE THE GLOBAL LIPIDS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030 66
FIGURE 12 TESTING SERVICES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL LIPIDS MARKET IN 2023 & 2030 66
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL LIPIDS MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030 67
FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR LIPIDS MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2023 TO 2030 68
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL LIPIDS MARKET 88
FIGURE 16 GLOBAL LIPIDS MARKET: BY TYPE, 2022 95
FIGURE 17 GLOBAL LIPIDS MARKET: BY TYPE, 2023-2030 (USD MILLION) 96
FIGURE 18 GLOBAL LIPIDS MARKET: BY TYPE, CAGR (2023-2030) 96
FIGURE 19 GLOBAL LIPIDS MARKET: BY TYPE, LIFELINE CURVE 97
FIGURE 20 GLOBAL LIPIDS MARKET: BY LIPID SYSTEMS, 2022 102
FIGURE 21 GLOBAL LIPIDS MARKET: BY LIPID SYSTEMS, 2023-2030 (USD MILLION) 103
FIGURE 22 GLOBAL LIPIDS MARKET: BY LIPID SYSTEMS, CAGR (2023-2030) 103
FIGURE 23 GLOBAL LIPIDS MARKET: BY LIPID SYSTEMS, LIFELINE CURVE 104
FIGURE 24 GLOBAL LIPIDS MARKET: BY DELIVERY SYSTEMS, 2022 118
FIGURE 25 GLOBAL LIPIDS MARKET: BY DELIVERY SYSTEMS, 2023-2030 (USD MILLION) 119
FIGURE 26 GLOBAL LIPIDS MARKET: BY DELIVERY SYSTEMS, CAGR (2023-2030) 119
FIGURE 27 GLOBAL LIPIDS MARKET: BY DELIVERY SYSTEMS, LIFELINE CURVE 120
FIGURE 28 GLOBAL LIPIDS MARKET: BY SOURCE, 2022 132
FIGURE 29 GLOBAL LIPIDS MARKET: BY SOURCE, 2023-2030 (USD MILLION) 133
FIGURE 30 GLOBAL LIPIDS MARKET: BY SOURCE, CAGR (2023-2030) 133
FIGURE 31 GLOBAL LIPIDS MARKET: BY SOURCE, LIFELINE CURVE 134
FIGURE 32 GLOBAL LIPIDS MARKET: BY END USER, 2022 142
FIGURE 33 GLOBAL LIPIDS MARKET: BY END USER, 2023-2030 (USD MILLION) 143
FIGURE 34 GLOBAL LIPIDS MARKET: BY END USER, CAGR (2023-2030) 143
FIGURE 35 GLOBAL LIPIDS MARKET: BY END USER, LIFELINE CURVE 144
FIGURE 36 GLOBAL LIPIDS MARKET: BY DISTRIBUTION CHANNEL, 2022 150
FIGURE 37 GLOBAL LIPIDS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 151
FIGURE 38 GLOBAL LIPIDS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 151
FIGURE 39 GLOBAL LIPIDS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 152
FIGURE 40 GLOBAL LIPIDS MARKET: SNAPSHOT (2022) 158
FIGURE 41 GLOBAL LIPIDS MARKET: BY REGION (2022) 160
FIGURE 42 GLOBAL LIPIDS MARKET: BY REGION (2023 & 2030) 160
FIGURE 43 GLOBAL LIPIDS MARKET: BY REGION (2022 & 2030) 161
FIGURE 44 GLOBAL LIPIDS MARKET: BY TYPE (2023-2030) 161
FIGURE 45 NORTH AMERICA LIPIDS MARKET: SNAPSHOT (2022) 164
FIGURE 46 NORTH AMERICA LIPIDS MARKET: BY COUNTRY (2022) 166
FIGURE 47 NORTH AMERICA LIPIDS MARKET: BY COUNTRY (2023 & 2030) 166
FIGURE 48 NORTH AMERICA LIPIDS MARKET: BY COUNTRY (2022 & 2030) 167
FIGURE 49 NORTH AMERICA LIPIDS MARKET: BY TYPE (2023 & 2030) 167
FIGURE 50 EUROPE LIPIDS MARKET: SNAPSHOT (2022) 197
FIGURE 51 EUROPE LIPIDS MARKET: BY COUNTRY (2022) 199
FIGURE 52 EUROPE LIPIDS MARKET: BY COUNTRY (2023 & 2030) 199
FIGURE 53 EUROPE LIPIDS MARKET: BY COUNTRY (2022 & 2030) 200
FIGURE 54 EUROPE LIPIDS MARKET: BY TYPE (2023 & 2030) 200
FIGURE 55 ASIA-PACIFIC LIPIDS MARKET: SNAPSHOT (2022) 280
FIGURE 56 ASIA-PACIFIC LIPIDS MARKET: BY COUNTRY (2022) 282
FIGURE 57 ASIA-PACIFIC LIPIDS MARKET: BY COUNTRY (2023 & 2030) 282
FIGURE 58 ASIA-PACIFIC LIPIDS MARKET: BY COUNTRY (2022 & 2030) 283
FIGURE 59 ASIA-PACIFIC LIPIDS MARKET: BY TYPE (2023 & 2030) 283
FIGURE 60 SOUTH AMERICA LIPIDS MARKET: SNAPSHOT (2022) 363
FIGURE 61 SOUTH AMERICA LIPIDS MARKET: BY COUNTRY (2022) 365
FIGURE 62 SOUTH AMERICA LIPIDS MARKET: BY COUNTRY (2023 & 2030) 365
FIGURE 63 SOUTH AMERICA LIPIDS MARKET: BY COUNTRY (2022 & 2030) 366
FIGURE 64 SOUTH AMERICA LIPIDS MARKET: BY TYPE (2023 & 2030) 366
FIGURE 65 MIDDLE EAST AND AFRICA LIPIDS MARKET: SNAPSHOT (2022) 390
FIGURE 66 MIDDLE EAST AND AFRICA LIPIDS MARKET: BY COUNTRY (2022) 392
FIGURE 67 MIDDLE EAST AND AFRICA LIPIDS MARKET: BY COUNTRY (2023 & 2030) 392
FIGURE 68 MIDDLE EAST AND AFRICA LIPIDS MARKET: BY COUNTRY (2022 & 2030) 393
FIGURE 69 MIDDLE EAST AND AFRICA LIPIDS MARKET: BY TYPE (2023 & 2030) 393
FIGURE 70 GLOBAL LIPIDS MARKET: COMPANY SHARE 2022 (%) 437
FIGURE 71 NORTH AMERICA LIPIDS MARKET: COMPANY SHARE 2022 (%) 438
FIGURE 72 EUROPE LIPIDS MARKET: COMPANY SHARE 2022 (%) 439
FIGURE 73 ASIA-PACIFIC LIPIDS MARKET: COMPANY SHARE 2022 (%) 440